Skip to content
Review

Blood-based biomarkers in Alzheimer's and Parkinson's disease: From molecular pathology to therapeutic potential.

2026 · International review of neurobiology · Vol 191, pp. 225-273 · 0 citations
Medicine

TL;DR

This chapter highlights a overview of blood-based biomarkers emerging in the field of AD and PD, exploring the clinical utility of core pathology markers (Aβ42/40, p-tau species, and α-synuclein), alongside other neurodegenerative markers such as neurofilament light chain and glial activation markers like GFAP.

View source

Similar papers

Review 2026

The clinical utility of blood-based biomarkers of Alzheimer's disease: Triumphs and pitfalls.

This chapter examines the clinical utility of key blood-based biomarkers, including phosphorylated tau, amyloid-β ratios, neurofilament light chain, and glial fibrillary acidic protein, within the context of current diagnostic frameworks.

M. M. Mir, Gulzar Muzaffar Mir, Abdul Majid et al. · 0 citations
Review 2026

Circulating biochemical signatures of neurodegeneration in Alzheimer's disease.

The blood-based biomarkers represent a transformative step toward early diagnosis, large-scale screening, and precision medicine in AD, with significant potential for the development of disease-modifying therapies.

Greata Rubavathi Eliazer, Mahesh Kandasamy · 0 citations
Review Open access Sep 2026

Alzheimer’s Disease in the Era of Geroscience: Mechanisms, Biomarkers, and Therapeutic Prospects

This narrative review examines AD mechanisms, biomarkers, and therapeutic prospects from a geroscience perspective and applies the eight hallmarks of neurodegenerative diseases as an analytical framework to establish which preventive strategies and biomarker-guided, stage-matched combination therapies improve clinicall...

P. Chmielewski · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.